A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

NCT06225115 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Dysfunction
Schizophrenia

Interventions

DRUG: KYN-5356
DRUG: placebo

Sponsor

Kynexis B.V.

Collaborators

[object Object]